In a strategic move that could reshape India’s diagnostics landscape, Reliance Industries Ltd. (RIL) is preparing to enter the genomic diagnostics space with a focus on making genetic tests significantly more affordable. The conglomerate plans to use its ownership of Strand Life Sciences, a Bengaluru-based genomics and diagnostics company it acquired in 2021, to drive this initiative and offer patients cutting-edge genomic insights without prohibitive costs. 

Market watchers say Reliance’s vision includes offering basic genomic tests at prices below ₹1,000 a nearly ten-fold reduction from current basic test costs of around ₹10,000 which could drastically expand access for a wider population. This pricing disruption echoes the strategy Reliance used with its telecom venture, lowering barriers to adoption and rapidly scaling usage across diverse income segments.

Genomic tests analyse DNA to reveal critical insights into disease risk, inherited conditions, cancer progression patterns and personalised health responses, which are increasingly central to preventive care and precision medicine. Reliance’s push aims to democratise such testing, bringing it into regular health screening rather than limiting it to specialised or research settings. The company’s approach could ultimately support earlier interventions, personalised therapy decisions and broader public engagement with genomic health data. 

Officials and executives involved with the plan view genomic diagnostics as a vital frontier in healthcare, and a dramatically lower price point combined with Reliance’s vast consumer network may help overcome cost and accessibility barriers that have constrained widespread use of genetic tests in India. If realised, this initiative could place genomic screening within reach of millions of people and fuel innovation in preventive and personalised healthcare across the country.